Exhibit 31.1 CERTIFICATION

I, Kelly T. Hickel, Chief Executive Officer of TheraBiogen, Inc. (the "Company" or "Registrant) certify that:

1. I have reviewed this quarterly report on Form 10-Q of the Company;

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this quarterly report;

4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:

(a) Designed such disclosure controls and procedures, or

caused such disclosure controls and procedures to be designed

under my supervision, to ensure that material information

relating to the registrant, is made known to us by others within

Company, particularly during the period in which this report is

being prepared;

(b) Designed such internal control over financial

reporting, or caused such internal control over financial

reporting to be designed under our supervision, to provide

reasonable assurance regarding the reliability of financial

reporting and the preparation of financial statements for

external purposes in accordance with generally accepted

accounting principles;

disclosure controls and procedures and presented in this report

our conclusions about the effectiveness of the disclosure

controls and procedures, as of the end of the period covered by

this report based on such evaluation; and

(d) Disclosed in this report any change in the

registrant's internal control over financial reporting that

occurred during the Company's fourth fiscal quarter that has

materially affected, or is reasonably likely to materially

affect, the Company's internal control over financial reporting; and

5. The Registrant's other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the

equivalent function):

a. all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's ability to record, process, summarize and report financial data and have identified for the registrant's auditors any material weaknesses in internal controls;

and

b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls; and

6. The Registrant's other certifying officers and I have indicated in this annual report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

Date: November 10, 2009 /s/ Kelly T. Hickel

-----------------------------

Kelly T. Hickel,

Chief Executive Officer

TheraBiogen, Inc. 10-Q